Clinical Trial Update: Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of ibrutinib, lenalidomide, and dexamethasone in multiple myeloma patients ineligible for transplant; the study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• IMBRUVICA (IBRUTINIB)
• Revlimid (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: TERMINATED